← All trials
NCT04925687
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2021
- Primary completion
- Jun 30, 2022
- Completion date
- Jun 30, 2022
- First posted
- Jun 14, 2021
- Last posted
- Aug 23, 2021
- Enrollment
- 4
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, DavisLead sponsor
- University of California, DavisReponsible party - principal investigator
- University of California, DavisOverall official - principal investigator
- Cures Within ReachCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.